Multiple Myeloma vs Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance are easy to mix up on the boards. Here's a side-by-side comparison — presentation, workup, imaging, and first-line treatment — drawn from our full outlines.
Multiple Myeloma vs Monoclonal Gammopathy of Undetermined Significance at a glance
- Multiple Myeloma: Clonal plasma cell malignancy with monoclonal protein, lytic bone disease, hypercalcemia, anemia, and renal failure (CRAB).
- Monoclonal Gammopathy of Undetermined Significance: Asymptomatic premalignant plasma cell disorder with monoclonal protein <3 g/dL, marrow plasma cells <10%, no end-organ damage.
Keep comparing — start your free trial
You've used your 2 free previews. Create your free account to see the full Multiple Myeloma vs Monoclonal Gammopathy of Undetermined Significance comparison — plus all 514 diagnosis outlines, 6,400+ board-style questions, and an AI tutor. Your 7-day free trial includes everything, no credit card required.
Side-by-side comparison
| Feature | Multiple Myeloma | Monoclonal Gammopathy of Undetermined Significance |
|---|---|---|
| At a glance | Clonal plasma cell malignancy with monoclonal protein, lytic bone disease, hypercalcemia, anemia, and renal failure (CRAB). | Asymptomatic premalignant plasma cell disorder with monoclonal protein <3 g/dL, marrow plasma cells <10%, no end-organ damage. |
| Classic presentation | Older adult with back pain, anemia, renal failure, hypercalcemia, and 'punched-out' lytic skull lesions on X-ray (Rouleaux formation on smear, M-spike on SPEP).; Bone pain — back, ribs, long bones; worse with movement; pathologic fractures (vertebral compression common); Fatigue from anemia; Frequent infections (encapsulated organisms —… | Incidental M-spike on serum protein electrophoresis (SPEP) in an asymptomatic older adult.; Asymptomatic — typically discovered incidentally on workup for elevated total protein, neuropathy, or unrelated illness; Rarely associated symptoms: peripheral neuropathy (especially IgM MGUS with anti-MAG antibodies); No specific findings; No… |
| Workup / key labs | Clonal plasma cells ≥10% in marrow (or biopsy-proven plasmacytoma) PLUS ≥1 of: hyperCalcemia (Ca >11 or >1 mg/dL above normal), Renal insufficiency (Cr >2 mg/dL or eGFR <40 attributable to MM), Anemia (Hb <10 or >2 g/dL below normal), Bone lesions (≥1 lytic lesion on imaging), OR myeloma-defining biomarkers (clonal plasma cells ≥60%,… | IMWG criteria — ALL three required: 1) Serum M-protein <3 g/dL 2) Clonal bone marrow plasma cells <10% 3) Absence of myeloma-defining events: hypercalcemia, renal dysfunction, anemia, bone lesions (CRAB); plus absence of amyloidosis or other plasma cell disorder. Subtypes: non-IgM MGUS (IgG, IgA), IgM MGUS, and light chain MGUS.; Serum… |
| Imaging | Whole-body low-dose CT, PET/CT, or whole-body MRI — preferred over plain skeletal survey for lytic lesion detection; MRI spine if cord compression suspected (urgent); Plain X-rays show 'punched-out' lytic lesions classically (skull, vertebrae, ribs, long bones); Echocardiogram if cardiac amyloidosis suspected | Whole-body low-dose CT, MRI, or PET-CT to evaluate for lytic lesions if intermediate/high-risk MGUS, IgA or light chain isotype, or symptomatic — replaces traditional skeletal survey; Cardiac MRI / echocardiogram if amyloidosis suspected (NT-proBNP, troponin, FLC ratio) |
| First-line treatment | Induction (transplant-eligible): proteasome inhibitor + immunomodulatory drug + dexamethasone + anti-CD38 monoclonal — quadruplet regimens (D-RVd: daratumumab + lenalidomide + bortezomib + dexamethasone) standard per PERSEUS and GRIFFIN trials; Induction (transplant-ineligible older patients): VRd or D-Rd (daratumumab + lenalidomide +… | NO TREATMENT — observation only; Risk-stratified surveillance based on Mayo Clinic risk model (non-IgG isotype, M-protein ≥1.5 g/dL, abnormal FLC ratio); 0 risk factors (low risk) — repeat SPEP in 6 months, then every 2-3 years if stable; 1-3 risk factors (intermediate to high risk) — annual SPEP indefinitely; consider baseline bone… |
Drill Multiple Myeloma vs Monoclonal Gammopathy of Undetermined Significance questions on FirstPassPA
Turn this comparison into retention. 6,400+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Try today's free questionEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.